{"id":"W2030987445","doi":"10.1186/s12931-014-0123-0","title":"Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study","year":2014,"lang":"en","type":"article","venue":"Respiratory Research","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Takeda Pharmaceuticals International; GlaxoSmithKline; Actavis; Almirall; Ironwood Pharmaceuticals, Incorporated; Forest Research Institute; Sunovion; Sanofi; Forest Laboratories; Mylan; AstraZeneca; Pfizer","keywords":"Formoterol; Medicine; Formoterol Fumarate; COPD; Fixed-dose combination; Dry-powder inhaler; Tolerability; Placebo; Muscarinic antagonist; Inhaler; Anesthesia; Adverse effect; Internal medicine; Asthma; Inhalation; Antagonist; Budesonide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003026141,0.002770904,0.005986986,0.000805993,0.000684779,0.001396622,0.001807015,0.003763429,0.006461405],"category_scores_gemma":[0.00256123,0.001325828,0.00259356,0.0005675082,0.002032189,0.001417015,0.0006442954,0.003645374,0.001469537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008133441,"about_ca_system_score_gemma":0.00134991,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008205817,"about_ca_topic_score_gemma":0.001179551,"domain_scores_codex":[0.9987655,0.000643078,0.00008686348,0.0002367463,0.0001128376,0.0001549239],"domain_scores_gemma":[0.9980124,0.0005137804,0.00051196,0.0002359054,0.0001878765,0.0005380941],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9818725,0.01022076,0.0002516507,0.0002330123,0.0003907645,0.00001814832,0.00002158505,0.00008926877,0.002716257,0.00001700017,0.0001640702,0.00400508],"study_design_scores_gemma":[0.9326064,0.06574035,0.0008410941,0.000008297204,0.0002225415,0.00001081311,0.000007337201,0.00009522072,0.0002694024,0.00002205564,0.0001680618,0.000008505242],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910361,0.002454342,0.0004967315,0.0003163705,0.0003737377,0.00363824,0.0008652451,0.0001124077,0.0007070052],"genre_scores_gemma":[0.9799541,0.002368363,0.002146339,0.0009741781,0.001053748,0.008138182,0.001399397,0.0000510446,0.003914694],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006461405,"threshold_uncertainty_score":0.02161556,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05672925672933922,"score_gpt":0.3655891636817695,"score_spread":0.3088599069524303,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}